blank LMU Munich Faculty for Chemistry and Pharmacy
print
 

Funding

The Merkel Lab is currently funded by the following grants:

European Research Council
ERC-2014-StG – 637830 October 2015 until September 2020
Biocompatible nanoparticles for T cell targeted siRNA delivery as novel asthma therapy
The goal of this study is to develop an inhalable powder therapy of nanoparticles that deliver siRNA against the Th2 transcription factor GATA-3 specifically into activated T cells ex vivo and in vivo to inhibit the downstream inflammatory cascades.
PI: Olivia Merkel

Else-Kröner-Foundation
2014_A299 July 2016 until June 2018
Novel Carrier Systems for Delivery of Biologics across the Blood Brain Barrier
The goal of this study is to develop novel carrier systems that encapsulate nucleic acids, proteins and both for therapeutic delivery across the BBB for the treatment of Alzheimer’s disease.
PI: Fricker, co-PIs: Merkel, Müller

Nanosystems Initiative Munich January 2017 until October 2017
Cellular Delivery Strategies of a Novel Kras Inhibitor
The aim of this study is to formulate a small molecule that has been shown to inhibit Kras in vitro as biodegradable nanoparticles for in vitro and in vivo Kras inhibition.
PIs: Vollmar and Merkel

Nanosystems Initiative Munich January 2017 until October 2017
Multifunctional mesoporous silica nanoparticles for siRNA delivery against TNFα as potential therapy for rheumatoid arthritis
The aim of this study is to develop MSNs that are loaded with siRNA and targeted toward activated macrophages for TNFa downregulation.
PIs: Merkel and Bein

Deutsche Gesellschaft für Muskelkranke
Me7/1 May 2017 until April 2018
Genome editing for DMPK-CTG-repeat expansion via receptor mediated targeted delivery of CRISPR-Cas9 vectors to myoblasts
The aim of this study is to develop CRISPR-Cas9 nanoparticles targeted toward myoblasts for replacement genome editing of repeat units as potential treatment for muscular dystrophy.
PI: Merkel

Fondazione Ricerca Fibrosi Cistica
FFC#23/2017 September 2017 until August 2018
Enabling pulmonary delivery of siRNA in cystic fibrosis lung inflammation: therapeutic potential of hybrid lipid/polymer nanoparticles
The aim of this study is to develop lipid/polymer hybrid nanoparticles for pulmonary delivery of siRNA against NFkB to address lung inflammation in cystic fibrosis.
PIs: Ungaro, Merkel